MRKR:NASDAQMarker Therapeutics, Inc. Analysis
Data as of 2026-06-30 - not real-time
$1.46
Latest Price
8/10Risk
Risk Level: High
Executive Summary
Marker Therapeutics trades at $1.46, comfortably above its 20‑day (1.39), 50‑day (1.44) and 200‑day (1.36) simple moving averages, and the RSI sits at 56.7, suggesting modest bullish momentum. The MACD histogram has turned positive and the signal is flagged as bullish, yet trading volume is on a decreasing trend and 30‑day volatility is elevated at over 52%, indicating a fragile price base.
Fundamentally, the company reports negative margins (gross -2.2%, operating -3.4%) and a trailing EPS of -$0.55, with a forward PE of -8.6, underscoring ongoing losses despite a cash balance of $14.9 M and no debt. The market’s extreme greed sentiment (FGI 89.9) and a consensus upside potential of roughly 440% (target median $8.00) create a speculative allure, but the high max drawdown of 55% and a beta above 1 amplify risk.
Fundamentally, the company reports negative margins (gross -2.2%, operating -3.4%) and a trailing EPS of -$0.55, with a forward PE of -8.6, underscoring ongoing losses despite a cash balance of $14.9 M and no debt. The market’s extreme greed sentiment (FGI 89.9) and a consensus upside potential of roughly 440% (target median $8.00) create a speculative allure, but the high max drawdown of 55% and a beta above 1 amplify risk.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 5/10
Key Factors
- Technical indicators show mild bullishness but volume is weakening
- High short‑term volatility and large recent drawdown
- Negative earnings and cash burn limit upside without catalyst
Medium Term
1–3 yearsNeutral
Model confidence: 6/10
Key Factors
- Potential value catalyst from Phase 1 trial readouts
- Cash runway sufficient for near‑term R&D
- Market pricing reflects a large upside premium that may compress
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Bi‑modal upside scenario if MAR‑T cell platform validates clinically
- Undervalued relative to target price and peer biotech multiples
- Long‑term growth narrative despite current losses
Key Metrics & Analysis
Financial Health
P/E Ratio-8.6
ROE-77.04%
ROA-43.59%
P/B Ratio1.8
Op. Cash Flow$-7918536
Free Cash Flow$-5248198
Industry P/E25.9
Technical Analysis
TrendNeutral
RSI56.7
Support$1.31
Resistance$1.57
MA 20$1.39
MA 50$1.44
MA 200$1.36
MACDBullish
VolumeDecreasing
Fear & Greed Index89.91
Valuation
Target Price$7.87
Upside/Downside438.81%
GradeUndervalued
TypeGrowth
Risk Assessment
Beta1.14
Volatility52.62%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.